C16H20N6O2
Neat
328.38
2028267-73-2; CP-690550N-oxide; (R)-N-((3R, 4R)-1-(2-Cyanoacetyl)-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2, 3-d]pyrimidin-4-amine oxide; N-((3R, 4R)-1-(2-CYANOACETYL)-4-METHYLPIPERIDIN-3-YL)-N-METHYL-7H-PYRROLO[2, 3-D]PYRIMIDIN-4-AMINE OXIDE; Tofacitinib N-oxide; Tofacitinib Impurity 24; VW58ZD3YDU; SCHEMBL28096251; N-((3R, 4R)-1-(2-cyanoacetyl)-4-methylpiperidin-3-yl)-N-methyl- 7H-pyrrolo[2, 3-d]pyrimidin-4-amine oxide; CS-0164344; F78338; (3R, 4R)-4-Methyl-3-(methyloxido-7H-pyrrolo[2, 3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidinepropanenitrile; 1-Piperidinepropanenitrile, 4-methyl-3-(methyloxido-7H-pyrrolo[2, 3-d]pyrimidin-4-ylamino)-beta-oxo-, (3R, 4R)-; N-((3R, 4R)-1-(2-cyanoacetyl)-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2 and 3-d]pyrimidin-4-amine oxide (Tofacitinib Impurity pound(c)
N-[(3R, 4R)-1-(2-cyanoacetyl)-4-methylpiperidin-3-yl]-N-methyl-7H-pyrrolo[2 and 3-d]pyrimidin-4-amine oxide
InChI=1S/C16H20N6O2/c1-11-5-8-21(14(23)3-6-17)9-13(11)22(2,24)16-12-4-7-18-15(12)19-10-20-16/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20)/t11-,13+,22?/m1/s1